Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma
Claudio R Scafoglio,Brendon Villegas,Gihad Abdelhady,Sean T Bailey,Jie Liu,Aditya S Shirali,W Dean Wallace,Clara E Magyar,Tristan R Grogan,David Elashoff,Tonya Walser,Jane Yanagawa,Denise R Aberle,Jorge R Barrio,Steven M Dubinett,David B Shackelford
DOI: https://doi.org/10.1126/scitranslmed.aat5933
2018-11-14
Abstract:The diagnostic definition of indeterminate lung nodules as malignant or benign poses a major challenge for clinicians. We discovered a potential marker, the sodium-dependent glucose transporter 2 (SGLT2), whose activity identified metabolically active lung premalignancy and early-stage lung adenocarcinoma (LADC). We found that SGLT2 is expressed early in lung tumorigenesis and is found specifically in premalignant lesions and well-differentiated adenocarcinomas. SGLT2 activity could be detected in vivo by positron emission tomography (PET) with the tracer methyl 4-deoxy-4-[18F] fluoro-alpha-d-glucopyranoside (Me4FDG), which specifically detects SGLT activity. Using a combination of immunohistochemistry and Me4FDG PET, we identified high expression and functional activity of SGLT2 in lung premalignancy and early-stage/low-grade LADC. Furthermore, selective targeting of SGLT2 with FDA-approved small-molecule inhibitors, the gliflozins, greatly reduced tumor growth and prolonged survival in autochthonous mouse models and patient-derived xenografts of LADC. Targeting SGLT2 in lung tumors may intercept lung cancer progression at early stages of development by pairing Me4FDG PET imaging with therapy using SGLT2 inhibitors.